APDN Earnings Prediction
The chart below shows how APDN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, APDN sees a -6.95% change in stock price 10 days leading up to the earnings, and a -15.39% change 10 days following the report. On the earnings day itself, the stock moves by -0.32%. This data can give you a slight idea of what to expect for the next quarter's release.
APDN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
797.52K
-72.66%
-14.21%
Gross Margin
30.75%
-29.33%
-3.30%
Operating Margin
-419.64%
328.20%
7.83%
Net Margin
231.91%
317.25%
-147.98%
EPS
0.47
295.83%
-100.44%
No Data Available
APDN Earnings Analysis
Applied DNA Sciences, Inc. Corporation (APDN.O) Earnings Conference Call
Positive
Applied DNA Sciences achieved a substantial increase in cash and cash equivalents, totaling $10.4 million on June 30, 2024, compared to $7.2 million on September 30, 2023, which included net proceeds from a public offering.
Applied DNA Sciences entered into a multi-year agreement with a global cotton apparel manufacturer, Indus, to supply DNA tagging and testing services, potentially representing a substantial expansion of the addressable market. The partnership aims to provide sustainable growth in this business segment due to Indus's large volume-based demand and compliance with regulations such as the Uyghur Forced Labor Prevention Act.
Applied DNA Sciences launched TR8 PGx, a pharmacogenomic testing service, with the capacity to support up to $25 million in annual revenue. Despite the lengthy New York State Department of Health approval process, the company is focused on targeting enterprise and large population contracts to avoid price pressures common in commoditized diagnostics.
Applied DNA Sciences continues to develop its enzymatic GMP production of DNA IVT templates, with a target completion date for its GMP facility by September 30. This strategic focus on biotherapeutics and Linea IVT platform is expected to drive commercial milestones and potentially deliver year-over-year revenue growth starting in the first half of fiscal 2025.
Negative
- Total revenues for the third quarter of fiscal '24 declined by $2.1 million compared to the same period in the prior fiscal year.
- Gross profit decreased primarily due to a decline in NDX Testing Services segment related to significantly decreased COVID-19 testing volumes year-over-year.
- Operating loss for the third quarter was $3.3 million compared to $2.9 million in the prior fiscal period.
- Excluding noncash expenses, adjusted EBITDA decreased by $1.1 million to negative $3.2 million compared to a negative $2.1 million in the prior fiscal year period.
- Cash burn increased during the third quarter of fiscal 2024 to an average monthly cash burn of $1.3 million compared to $500,000 in the prior year.
APDN FAQs
How does APDN typically perform around its earnings report dates?
Is Applied DNA Sciences, Inc. (APDN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
APDN Earning Call Sentiment
Applied DNA Sciences, Inc. (APDN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
APDN.O
-0.12%Positive
The earnings call summary highlights several concerns: substantial revenue decline, increased cash burn rate, and doubts about the company's ability to continue as a going concern. Regulatory delays and competitive pressures further exacerbate these issues. The Q&A section reveals management's lack of clarity on future customer uptake and test volumes, adding to uncertainties. Despite the potential for additional proceeds from warrant exercises, the overall sentiment is negative due to financial struggles, market competition, and regulatory hurdles. The stock is likely to experience a negative movement of -2% to -8% over the next two weeks.